Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
36.04
-0.65 (-1.77%)
Aug 4, 2025, 10:13 AM - Market open
Aerovate Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Aerovate Therapeutics stock have a consensus rating of "Buy" and an average price target of $70.92, which forecasts a 96.78% increase in the stock price over the next year. The lowest target is $41 and the highest is $120.
Price Target: $70.92 (+96.78%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 9, 2025.
Analyst Ratings
The average analyst rating for Aerovate Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Buy | 9 | 9 | 10 | 7 | 7 | 7 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 18 | 16 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $71 → $53 | Buy | Maintains | $71 → $53 | +47.06% | Jun 9, 2025 |
| Mizuho | Mizuho | Buy Maintains $103 → $84 | Buy | Maintains | $103 → $84 | +133.07% | May 29, 2025 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +99.78% | May 14, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $53 | Buy | Maintains | $55 → $53 | +47.06% | May 8, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $82 → $80 | Buy | Maintains | $82 → $80 | +121.98% | May 7, 2025 |
Financial Forecast
Revenue This Year
23.48M
from 18.47M
Increased by 27.08%
Revenue Next Year
176.56M
from 23.48M
Increased by 652.09%
EPS This Year
-5.61
from -5.26
EPS Next Year
-5.13
from -5.61
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.2M | 415.8M | 742.0M | ||
| Avg | 23.5M | 176.6M | 427.8M | ||
| Low | 1.5M | 47.0M | 213.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 404.7% | 1,671.2% | 320.3% | ||
| Avg | 27.1% | 652.1% | 142.3% | ||
| Low | -91.6% | 100.4% | 20.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.28 | -3.02 | -0.53 | ||
| Avg | -5.61 | -5.13 | -3.30 | ||
| Low | -6.47 | -6.75 | -5.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.